Featured News

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.

Thanks to your generous support, we are deploying iCureCeliac and iQualifyCeliac, as well as other assets unique to the Foundation, to further celiac disease drug development.

CDF has been approved for a $100,000 funding award through the Eugene Washington PCORI Engagement Awards program. The funds will support the community convening of patient advocates, researchers, and other key stakeholders to create a roadmap for patient advocate engagement in research.

On Friday, I joined three of the leading celiac disease researchers in the world to present to the NIH’s Autoimmune Disease Coordinating Committee (ADCC) the findings from the CDF-sponsored First SSCD Consensus Workshop: Research Opportunities in Celiac Disease 2020.

We have been hearing from our community about COVID-19 and celiac disease and about our work at the Celiac Disease Foundation during the pandemic. We have answered the most frequently asked questions in a short video for you. 

Last week, one of our 2019 Young Investigator Award recipients, Dr. Benjamin Lebwohl, co-authored a study that showed a small, but statistically significant increase in mortality rates for patients with celiac disease.

A recent review found that overall, the incidence of celiac disease has been rising since the second half of the 20th century into the 21st century in nearly every country where data on the disease are available.

More and more evidence is showing what many have long suspected: maintaining a truly gluten-free diet may not be possible.